Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is filed by Addex Therapeutics Ltd., a foreign private issuer headquartered in Geneva, Switzerland. The report covers the month of February 2026, specifically referencing a press release issued on February 3, 2026 (Exhibit 99.1).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to incorporate a press release by reference rather than presenting a standalone financial statement.
Material Changes
The document does not detail specific material changes in financial performance or operations versus prior periods. It directs readers to the attached press release for the substance of the announcement.
Guidance, Outlook, and Risks
The filing includes standard risk factor disclosures, noting that the company's business, financial condition, and growth prospects could be materially adversely affected by risks detailed in its Annual Report on Form 20-F for the year ended December 31, 2024. It also contains forward-looking statements subject to uncertainties that may cause actual results to differ materially from anticipated outcomes.
Key Facts for Investor Verification
- Review the attached Press Release (Exhibit 99.1) dated February 3, 2026, for the specific announcement details.
- Consult the Annual Report on Form 20-F filed on May 15, 2025, for comprehensive risk factors and historical financial data.
- Verify the incorporation of this report into Registration Statements on Form F-3 (No. 333-291644) and Form S-8 (Nos. 333-255124 and 333-272515).